{
    "clinical_study": {
        "@rank": "120850", 
        "acronym": "CHF6001_POC2", 
        "arm_group": [
            {
                "arm_group_label": "Placebo DPI", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo by inhalation for 9 days"
            }, 
            {
                "arm_group_label": "CHF6001 DPI Dose 2", 
                "arm_group_type": "Experimental", 
                "description": "CHF6001 by inhalation for 9 days"
            }, 
            {
                "arm_group_label": "CHF6001 DPI Dose1", 
                "arm_group_type": "Experimental", 
                "description": "CHF6001 by inhalation for 9 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The study is designed to look at the safety, tolerability and efficacy of 2 different doses\n      of the study drug (CHF6001, a PDE4 inhibitor) in asthmatics, when given by inhalation, once\n      a day for 9 days. The efficacy will be evaluated by measuring the protective effect of CHF\n      6001 after an allergen challenge."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  written informed consent obtained\n\n          -  Non smoking or ex-smokers from at least 1 year prior to study entry\n\n          -  Males of females between 18 and 60 years inclusive\n\n          -  Body Mass Index between 18 and 32 kg/m2\n\n          -  Ability to be trained about the proper use of the inhalation device and to perform\n             spirometry\n\n          -  With mild to moderate allergic asthma as defined by the GINA guideline, steroid naive\n\n          -  Atopy to at least one common aeroallergen\n\n          -  Positive allergen-induced Early Asthmatic Response and Late Asthmatic Response at\n             screening\n\n          -  Ability to produce an adequate sputum sample\n\n          -  Post-menopausal women, women of not childbearing potential or males and females of\n             childbearing potential willing (they or their partner) to use a reliable method of\n             contraception.\n\n        Exclusion Criteria:\n\n          -  Worsening of asthma or respiratory tract infection prior to study entry\n\n          -  History of life-threatening asthma or hospitalization for asthma prior to the study\n             entry\n\n          -  Pregnant or lactating women\n\n          -  History of clinically significant hypotensive episodes or fainting, dizziness or\n             light-headedness\n\n          -  History or symptoms of clinically relevant neurologic disease\n\n          -  Symptomatic hay fever\n\n          -  Unstable concurrent disease that may impact the feasibility of the study\n\n          -  Use of systemic corticosteroids, nebulised bronchodilator or oral beta2-agonist\n\n          -  Use of leukotrienes modifiers, roflumilast or cromoglycate\n\n          -  Use of long acting beta2-agonist or inhaled corticosteroids\n\n          -  Use of short-acting or long-acting non-sedatives antihistamines\n\n          -  Use of any other medication for the treatment of allergic asthma other than\n             salbutamol\n\n          -  Having received an investigational medicinal drug within 30 days prior to study entry\n\n          -  Blood drawn of at least 250 ml in the previous 45 days\n\n          -  Ongoing use of tobacco\n\n          -  Other lung disease\n\n          -  Recent history of alcohol dependency\n\n          -  Inability to comply with the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689571", 
            "org_study_id": "CCD-1202-PR-0080", 
            "secondary_id": "2012-001483-29"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "CHF6001 DPI Dose 2", 
                    "CHF6001 DPI Dose1"
                ], 
                "intervention_name": "CHF6001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo DPI", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "PDE4 inhibitor", 
            "Allergen Challenge", 
            "Asthma"
        ], 
        "lastchanged_date": "May 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Respiratory Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Hammersmith Medicines Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Medicines Evaluation Unit"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma", 
        "other_outcome": [
            {
                "description": "The following parameters will be evaluated at the steady state: AUC0-t, AUC0-24h, Cmax, Cmin, Cav, tmax, tmin, t\u00bd, CL/F and Vz/F", 
                "measure": "Pharmacokinetics of CHF6001 and its metabolites", 
                "safety_issue": "No", 
                "time_frame": "after 9 days of treatment"
            }, 
            {
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "After single dose and 9 days of treatment"
            }, 
            {
                "measure": "ECG", 
                "safety_issue": "Yes", 
                "time_frame": "After single dose and 9 days of treatment"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "Medicines Evaluation Unit", 
                "last_name": "Dave Singh, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Respiratory Clinical Trials", 
                "last_name": "Brian Leaker, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Hammersmith Medicines Research", 
                "last_name": "Elizabeth Tranter, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Allergen challenge", 
            "safety_issue": "No", 
            "time_frame": "after 9 days of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689571"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Induced Sputum", 
                "safety_issue": "No", 
                "time_frame": "After 9 days of treatment"
            }, 
            {
                "measure": "Methacholine challenge", 
                "safety_issue": "No", 
                "time_frame": "After 9 days of treatment"
            }
        ], 
        "source": "Chiesi Farmaceutici S.p.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chiesi Farmaceutici S.p.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}